Skip to Main Content
Table I

TCR Vα Usage in Mutant TCR-β Transgenic Mice

Percent of CD4+Percent of CD8+
Vα2+Vα3.2+Vα8+Vα11+Vα2+Vα3.2+Vα8+Vα11+
β  22.7 ± 1.0  0.7 ± 0.2  3.0 ± 0.1  1.5 ± 0.4  7.7 ± 1.8  1.0 ± 0.1  4.5 ± 0.1  1.2 ± 0.2 
β-loop  22.7 ± 0.9  0.5 ± 0.1  2.6 ± 0.3  2.3 ± 0.3  7.6 ± 1.1  1.4 ± 0.6  3.6 ± 0.7  2.0 ± 0.3 
Percent of CD4+Percent of CD8+
Vα2+Vα3.2+Vα8+Vα11+Vα2+Vα3.2+Vα8+Vα11+
β  22.7 ± 1.0  0.7 ± 0.2  3.0 ± 0.1  1.5 ± 0.4  7.7 ± 1.8  1.0 ± 0.1  4.5 ± 0.1  1.2 ± 0.2 
β-loop  22.7 ± 0.9  0.5 ± 0.1  2.6 ± 0.3  2.3 ± 0.3  7.6 ± 1.1  1.4 ± 0.6  3.6 ± 0.7  2.0 ± 0.3 

Lymph node cells from TCR-β (β) or mutant TCR-β (β-loop) transgenic mice were triple stained with the FITC-labeled anti-Vα Abs, anti-CD4– PE, and anti-CD8–Cy5. Results (three mice per group) are expressed as the percentage of stained cells ± SD.  

Close Modal

or Create an Account

Close Modal
Close Modal